WO2002022864A1 - The method of detecting mutant dspp gene of hereditary opalescent - Google Patents

The method of detecting mutant dspp gene of hereditary opalescent Download PDF

Info

Publication number
WO2002022864A1
WO2002022864A1 PCT/CN2000/000280 CN0000280W WO0222864A1 WO 2002022864 A1 WO2002022864 A1 WO 2002022864A1 CN 0000280 W CN0000280 W CN 0000280W WO 0222864 A1 WO0222864 A1 WO 0222864A1
Authority
WO
WIPO (PCT)
Prior art keywords
dspp
primer
gene
detecting
mutant gene
Prior art date
Application number
PCT/CN2000/000280
Other languages
French (fr)
Chinese (zh)
Inventor
Yan Shen
Jun Zhao
Xiaohai Zhang
Original Assignee
Sinogenomax Co.,Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinogenomax Co.,Ltd filed Critical Sinogenomax Co.,Ltd
Priority to JP2002527304A priority Critical patent/JP3886901B2/en
Priority to CNB00819646XA priority patent/CN1257986C/en
Priority to DE10085485T priority patent/DE10085485B4/en
Priority to AU2000272670A priority patent/AU2000272670A1/en
Priority to PCT/CN2000/000280 priority patent/WO2002022864A1/en
Publication of WO2002022864A1 publication Critical patent/WO2002022864A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Definitions

  • the invention relates to a method for detecting a mutant gene dspp of hereditary opalescent dentin, and the method may be a direct sequencing method or a restriction enzyme method or an oligonucleotide probe hybridization method. More specifically, the present invention is a method for locating the mutation site of the hereditary opalescent tooth shield at the third exon of dspp. In addition, the present application also relates to a kit prepared according to the method of the present invention and the application of the kit to a method for detecting and treating hereditary opalescent dentin. Background technique
  • Hereditary opalescent dentin is an autosomal dominant hereditary disease with an incidence of 1/8000. In 1973, Shields classified it as Type 2 dentinogenesis imperfect type 11 (Dentinogenesis Imperfect Type 11). Both the primary and permanent teeth of the patient were affected, and the affected teeth were gray-blue or dark brown with a milky gloss. Under the X-ray film, you can see that the crown is spherical, the roots are smaller, the pulp chamber and root canal are narrowed or completely closed.
  • the pathogenic genes of hereditary opalescent dentin have been located in the 2 MB range on 4q21, and within this range 4 genes have been found to be involved in tissue mineralization. They are secreted phosphoprotein 1, SSPl, dentin matrix protein 1, DMPl, dentin sialophosphoprotein (DSPP) and bone saliva. Acid protein (bone sialoprotein, IBSP).
  • SSPl secreted phosphoprotein 1
  • DMPl dentin matrix protein
  • DSPP dentin sialophosphoprotein
  • IBSP Acid protein
  • the dspp genome sequence was recently determined (AF163151). dspp encodes DSP and DPP 2 proteins, of which DPP Highly phosphorylated, which is thought to regulate the shape and size of hydroxyapatite crystals, and plays an important role in the nucleation process of hydroxyapatite crystals.
  • the pathogenic gene of the family used in the present invention is mapped to chromosome 4q by linkage analysis. Then determine the genomic sequence of the first 4 exons of the candidate gene dspp in the patient and compare them with the normal control. It was found that there is a nonsense mutation in the third exon of dspp, so that the present invention finds heredity
  • the pathogenic gene of opalescent dentin is dspp. Since this mutation leads to a change in the recognition site of the restriction enzyme Rsal, this method provides convenience for detecting hereditary opalescent dentinopathy. And the invention lays a foundation for further research on the mineralization process of teeth and the pathogenic mechanism and treatment of hereditary opalescent dentin.
  • the present invention finds that the dspp gene is a disease-causing gene of hereditary opalescent dentin, which is the premise for further searching for other pathogenic mutations of the dspp gene in more hereditary opalescent dentin families, and is also the following More of the diagnostic kit The improvement has laid the foundation.
  • Another object of the present invention is to provide an application of a dspp mutant gene in the treatment of hereditary opalescent dentin.
  • Another object of the present invention is to provide a forward primer containing a reverse primer, a reverse primer on the inner side, a reverse primer on the inner side, a reverse primer on the inner side, a 10-fold PCR reaction buffer, dNTP, Taq DNA polymerase, MgCl according to the above method.
  • Restriction enzyme Rsal Restriction enzyme 10-fold reaction buffer, BSA kit.
  • the invention also provides the application of the above kit in a method for detecting and treating hereditary opalescent dentin.
  • the present invention links the dspp gene with hereditary opalescent dentin, and provides a new idea for the treatment of this disease.
  • relevant drugs that can regulate the mineralization of the teeth were synthesized for treatment. Brief description of the drawings
  • Figure 1 Family map of hereditary opalescent dentin.
  • the proband in the picture is indicated by the upper left tip, and the black icon represents the affected individual.
  • FIG. 1 Partial sequencing map of dspp genes from normal opalescent dentin patients with normal controls.
  • the left map is a partial map of the dspp of a normal individual, and the right is a sequencing picture of the patient's mutant dspp gene.
  • the eight STRPs are marked as: D4S2915, D4S2932, GATA62A11, D4S2409, DSP STRP, SPP1, D4S1563, D4S1544.
  • the primer sequences of eight STRPs are shown in Table 1. PCR was performed on a Perkin Elmer 9600 thermal cycler with the above 8 pairs of primers. The reaction system was 12.5 ⁇ 1 (10 x PCR buffer 1.25 ⁇ 1, 2 mmol / L dNTPs 0.5 ⁇ ld TP (product of Sigma)).
  • the PCR product can be separated from the polyacrylamide gel
  • the PCR products of different sites of the same individual are mixed, and the mixed product of the 2 ⁇ reaction is taken with a molecular weight standard of 0.4 ⁇ -400, 2.1 ⁇ formamide and 0.4 ⁇ Dye mix, 95 ° (denaturation 2 11 1,); water bath quickly cooled, electrophoresis on 4% polyacrylamide and 36% urea for 2 h on Perkin Elmer ABI377 sequencer, data collection using GENESCAN 2.1 software, lane line Calibration, intrinsic molecular weight calibration and migration fragment size measurement.
  • the 3581 calculates the Lod values when the recombination rates are 0, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4. Judging by the Lod value> 1, the pathogenic gene of hereditary opalescent dentin was located on chromosome 4q.
  • reaction conditions are:
  • the second round of PCR products was taken and directly sequenced using PCR primers as sequencing primers.
  • the obtained sequence map is analyzed. Where there are impurities and double peaks, it indicates that the site is heterogeneous and needs further analysis.
  • the sequences containing hetero and status sites were compared with those of Genebank and translated according to the normal reading frame. It was found that the patient had a nonsense mutation in exon III, in which the 3658th nucleotide of DSPP 3 exon was mutated from C to T, which caused the 45th position of dspp to be normally encoded by glutamine.
  • the first round of PCR reaction was performed with E34fout primers. After the reaction was completed, electrophoresis and photos were archived. Then take one round of the PCR product and dilute it 250 times, and use E341out for the second round of PCR reaction.
  • the reaction system is 100 ⁇ 1.
  • the reaction conditions are the same as those of the mutation screening section. Take the second round of PCR products for electrophoresis and take pictures for archiving.
  • PCR recovery kit is Life Technologies Concert Papid PCR Purfication System
  • wash buffer containing ethanol
  • centrifuge for 1 minute.
  • Discard the flow-out liquid 20 ° C, ll, 900g, and centrifuge for 1 minute.
  • the kit contains:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention involves a method of detecting mutant DSPP gene of hereditary opalescent dentin. The invention locates the mutation locus resulting in hereditary opalescent dentin in the third exon of dspp, and describes the application of said method in the diagnosis and therapy of hereditary opalescent dentin cases. Thereby the invention sets the foundation for further studies on the mineralizing process of teeth, nosogenetic mechanism of hereditary opalescent dentin, as well as their utilities in clinic and antenatal diagnosis. The invention also provides a kit and its use in the diagnosis and therapy of patients with hereditary opalescent dentin.

Description

检测遗传性乳光牙本质的突变基因 dspp 的方法 发明领域  Method for detecting mutated gene dspp of hereditary opalescent dentin FIELD OF THE INVENTION
本发明涉及一种检测遗传性乳光牙本质的突变基因 dspp 的方法, 该方 法可为直接测序法或限制性内切酶法或寡核苷酸探针杂交法。 更具体地说, 本发明是一种将遗传性乳光牙本盾的突变位点定位于 dspp 的第三个外显子 处的方法。 另外, 本申请还涉及了依据本发明的方法制备而成的试剂盒以 及试剂盒在遗传性乳光牙本质的检测与治疗方法中的应用。 背景技术  The invention relates to a method for detecting a mutant gene dspp of hereditary opalescent dentin, and the method may be a direct sequencing method or a restriction enzyme method or an oligonucleotide probe hybridization method. More specifically, the present invention is a method for locating the mutation site of the hereditary opalescent tooth shield at the third exon of dspp. In addition, the present application also relates to a kit prepared according to the method of the present invention and the application of the kit to a method for detecting and treating hereditary opalescent dentin. Background technique
遗传性乳光牙本质是一种常染色体显性遗传病, 发病率为 1/8000, 1973 年 Shields将其归为 II型牙本质生长不全 (Dentinogenesis Imperfect Type 11)。 患者的乳牙和恒牙均受到影响, 受累的牙齿呈灰蓝色或深棕色且伴有乳白 色光泽。 在 X光片下, 可以看到牙冠呈球形,牙根变小, 髓室和根管变窄或 完全闭锁。 牙釉质的形成尽管不受遗传性乳光牙本质的直接影响, 但是由 于牙本质和牙釉质的接触面从贝壳状变平, 使牙釉盾很容易从牙本质上脱 落, 使本来就发育不良的牙本质过快磨损, 牙齿显著变短, 严重者可磨低 至牙槽突。 由于过度磨损, 年龄较大的病人可出现牙槽骨的增生和牙龈的 增厚、 纤维性变。 结果, 遗传性乳光牙本质患者不得不接受广泛的牙齿护 理和昂贵的治疗。  Hereditary opalescent dentin is an autosomal dominant hereditary disease with an incidence of 1/8000. In 1973, Shields classified it as Type 2 dentinogenesis imperfect type 11 (Dentinogenesis Imperfect Type 11). Both the primary and permanent teeth of the patient were affected, and the affected teeth were gray-blue or dark brown with a milky gloss. Under the X-ray film, you can see that the crown is spherical, the roots are smaller, the pulp chamber and root canal are narrowed or completely closed. Although the formation of enamel is not directly affected by hereditary opalescent dentin, because the contact surface between dentin and enamel is flattened from a shell shape, the enamel shield is easily detached from the dentin, making it originally stunted The dentin wears off too quickly and the teeth become significantly shorter. In severe cases, they can be worn down to the alveolar process. Due to excessive wear, older patients may develop alveolar bone hyperplasia and gum thickening and fibrosis. As a result, patients with hereditary opalescent dentin have to undergo extensive dental care and expensive treatment.
遗传性乳光牙本质的致病基因已被定位在 4q21上的 2 MB的范围内, 在此范围内已发现 4 个基因与組织的矿化过程有关。 它们分别是分泌型焦 磚酸蛋白 ( secreted phosphoprotein 1, SSPl ),牙本盾基盾蛋白 1 ( dentin matrix protein 1, DMPl ), 牙本质唾液酸焦磚酸蛋白 (dentin sialophosphoprotein, DSPP ) 和骨唾液酸蛋白 (bone sialoprotein, IBSP )。 最近 dspp的基因组顺 序被测定完成(AF163151 )。 dspp编码 DSP和 DPP 2个蛋白质, 其中 DPP 高度磷酸化, 被认为可调节羟基磷灰石晶体的形状和大小, 在羟基磷灰石 晶体的成核过程中起着重要的作用。 The pathogenic genes of hereditary opalescent dentin have been located in the 2 MB range on 4q21, and within this range 4 genes have been found to be involved in tissue mineralization. They are secreted phosphoprotein 1, SSPl, dentin matrix protein 1, DMPl, dentin sialophosphoprotein (DSPP) and bone saliva. Acid protein (bone sialoprotein, IBSP). The dspp genome sequence was recently determined (AF163151). dspp encodes DSP and DPP 2 proteins, of which DPP Highly phosphorylated, which is thought to regulate the shape and size of hydroxyapatite crystals, and plays an important role in the nucleation process of hydroxyapatite crystals.
尽管 dspp的基因组被测定完成, 但是本领域却没有人利用直接测序法、 限制性内切酶法或寡核苷酸探针杂交法将遗传性乳光牙本质的突变位点定 位于 dspp的具体外显子处; 发明人选取 4q21 附近的 8个短串联重复序列 标记( STRP ), 进行连锁分析, 把本发明所用遗传性乳光牙本盾家系的致 病基因定位在染色体 4q。 通过对 dspp基因前 4个外显子及其旁侧的基因组 序列的测定, 发现了 1 个无义突变, 且突变造成了翻译的提前终止。 因为 限制性内切酶 Rsal具有识别突变与正常的 DNA序列的特点, 所以上述突 变可通过 Rsal酶切来检测。 通过对无义突变位点的检测, 从而为进一步研 究牙齿的矿化过程以及遗传性乳光牙本质的致病机理以及用于患者的临床 诊断或产前诊断奠定了基础。 另外, 发明人依据本发明的方法制备成一种 可准确快速诊断遗传性乳光牙本质疾病的试剂盒。 发明概述  Although the genome of dspp has been determined, no one in the art has used the direct sequencing method, restriction enzyme method or oligonucleotide probe hybridization method to locate the mutation site of hereditary opalescent dentin at the specific dspp At the exon; the inventor selected 8 short tandem repeat markers (STRP) near 4q21 and performed linkage analysis to locate the disease-causing gene of the hereditary opalescent tooth Shield family used in the present invention on chromosome 4q. By sequencing the first four exons of the dspp gene and the genomic sequences flanking it, a nonsense mutation was found, and the mutation caused premature termination of translation. Because the restriction enzyme Rsal recognizes mutations and normal DNA sequences, these mutations can be detected by Rsal digestion. The detection of nonsense mutation sites has laid a foundation for further research on the mineralization of teeth and the pathogenesis of hereditary opalescent dentin, as well as the clinical diagnosis or prenatal diagnosis for patients. In addition, the inventors prepared a kit capable of accurately and quickly diagnosing hereditary opalescent dentin diseases according to the method of the present invention. Summary of invention
本发明的一个目的是提供一种检测遗传性乳光牙本质的突变基因 dspp 的方法。  It is an object of the present invention to provide a method for detecting a mutant gene dspp of hereditary opalescent dentin.
在本发明一个方面, 通过连锁分析把本发明中所使用家系的致病基因 定位在染色体 4q。 然后测定侯选基因 dspp前 4个外显子在患者中的基因组 序列, 并于正常对照做比较, 发现在 dspp的第三个外显子中有一个无义突 变, 从而本发明找到了遗传性乳光牙本质的致病基因为 dspp。 由于该突变 导致了限制性内切酶 Rsal识别位点的改变, 所以该方法为检测遗传性乳光 牙本质病提供了方便。 并且本发明为进一步研究牙齿的矿化过程以及遗传 性乳光牙本质的致病机理及治疗奠定了基础。 另外, 本发明发现 dspp基因 是遗传性乳光牙本质的致病基因, 这是进一步在更多的遗传性乳光牙本盾 家系中寻找 dspp基因的其它致病突变的前提, 也为下述的诊断试剂盒的更 加完善奠定了基础。 In one aspect of the present invention, the pathogenic gene of the family used in the present invention is mapped to chromosome 4q by linkage analysis. Then determine the genomic sequence of the first 4 exons of the candidate gene dspp in the patient and compare them with the normal control. It was found that there is a nonsense mutation in the third exon of dspp, so that the present invention finds heredity The pathogenic gene of opalescent dentin is dspp. Since this mutation leads to a change in the recognition site of the restriction enzyme Rsal, this method provides convenience for detecting hereditary opalescent dentinopathy. And the invention lays a foundation for further research on the mineralization process of teeth and the pathogenic mechanism and treatment of hereditary opalescent dentin. In addition, the present invention finds that the dspp gene is a disease-causing gene of hereditary opalescent dentin, which is the premise for further searching for other pathogenic mutations of the dspp gene in more hereditary opalescent dentin families, and is also the following More of the diagnostic kit The improvement has laid the foundation.
本发明的另一个目的是提供一种 dspp 突变基因在遗传性乳光牙本质治 疗中的应用。  Another object of the present invention is to provide an application of a dspp mutant gene in the treatment of hereditary opalescent dentin.
本发明的再一个目的是依据上述方法提供一种含夕卜侧 forward primer, 夕卜侧 reverse primer、 内侧 forward primer、 内侧 reverse primer、 10倍 PCR 反应緩冲液、 dNTP、 Taq DNA聚合酶、 MgCl2、 限制性内切酶 Rsal、 限制 性内切酶 10倍反应緩冲液、 BSA的试剂盒。 通过使用该试剂盒在本发明发 现的无义突变附近设计 PCR引物, 进行 PCR反应, 再用限制性内切酶 Rsal 酶切 PCR产物, 即可简便快速的诊断此病。 该诊断试剂盒不但可使遗传性 乳光牙本质的临床诊断更加准确, 而且还可用于产前诊断。 Another object of the present invention is to provide a forward primer containing a reverse primer, a reverse primer on the inner side, a reverse primer on the inner side, a reverse primer on the inner side, a 10-fold PCR reaction buffer, dNTP, Taq DNA polymerase, MgCl according to the above method. 2. Restriction enzyme Rsal, Restriction enzyme 10-fold reaction buffer, BSA kit. By using the kit to design PCR primers near the nonsense mutations found in the present invention, to perform a PCR reaction, and then to cut the PCR product with the restriction enzyme Rsal, the disease can be diagnosed simply and quickly. The diagnostic kit can not only make the clinical diagnosis of hereditary opalescent dentin more accurate, but also can be used for prenatal diagnosis.
本发明还提供上述试剂盒在遗传性乳光牙本质的检测与治疗方法中的 应用。  The invention also provides the application of the above kit in a method for detecting and treating hereditary opalescent dentin.
另一方面, 本发明把 dspp基因和遗传性乳光牙本质联系起来, 为此病 的治疗提供了新的思路。 在进一步了解突变的 dspp基因致病的基础上, 合 成可调节牙齿矿化过程的相关药物进行治疗。 附图简述  On the other hand, the present invention links the dspp gene with hereditary opalescent dentin, and provides a new idea for the treatment of this disease. On the basis of further understanding the pathogenesis of the mutated dspp gene, relevant drugs that can regulate the mineralization of the teeth were synthesized for treatment. Brief description of the drawings
图 1.遗传性乳光牙本质家系图。 图中的先证者用左上尖头表示, 黑色 图标代表受累个体.  Figure 1. Family map of hereditary opalescent dentin. The proband in the picture is indicated by the upper left tip, and the black icon represents the affected individual.
图 2. 遗传性乳光牙本质患者 dspp基因与正常对照的部分测序图谱。 左 边图谱为正常个体的 dspp的部分图谱, 右边为患者的突变 dspp基因的部分 测序图语。  Figure 2. Partial sequencing map of dspp genes from normal opalescent dentin patients with normal controls. The left map is a partial map of the dspp of a normal individual, and the right is a sequencing picture of the patient's mutant dspp gene.
图 3. PCR产物经 Rsal酶切的酶切图谱。 左边第一个 +/+为对照 (Cont. ) 的酶切图谱; +/-为受累个体的酶切图谱; 其余 +/+为正常个体的的酶切图谱, 因其 dspp的无义突变破坏了 Rsal的识别位点,导致在琼脂糖电泳后出现一 条较大条带。 下面结合实施例, 进一步阐述本发明。 应理解, 下述实施例仅用于说 明本发明而不是用于来限制本发明。 实施例 Figure 3. Rsal digestion map of the PCR product. The first + / + on the left is the digestion map of the control (Cont.); +/- is the digestion map of the affected individuals; the rest + / + is the digestion map of normal individuals, because of the nonsense mutation of dspp. The recognition site of Rsal resulted in a larger band after agarose electrophoresis. The present invention is further described below in conjunction with the embodiments. It should be understood that the following examples are only used to illustrate the present invention and not intended to limit the present invention. Examples
实施例 1  Example 1
1. 遗传性乳光牙本质致病基因的定位:  1. Mapping of hereditary opalescent dentin-causing genes:
1.1 对象 所分析的遗传性乳光牙本质家系是在天津医科大学口腔医 院临床工作中发现的(图 1)。 此家系现存活 36人, 15人受累。 先证者 V2 , 男, 5 岁,乳牙还未全部脱落, 但髓腔根管已有闭锁趋势, 以前牙为明显。 乳牙过度磨损, 但未见根尖周阴影, 恒牙胚发育也未见异常。 患者临床表 现符合遗传性乳光牙本质的主要特征。 家系中的其他患者也具有该病的主 要特征。 致病基因传递规律符合常染色体显性遗传特征。 我们对其中 13 名 家庭成员 (其中患者 10名) 的 DNA进行了分析。  1.1 Subjects The hereditary opalescent dentin pedigree analyzed was discovered in clinical work at the Stomatological Hospital of Tianjin Medical University (Figure 1). There are 36 survivors in this family, and 15 are affected. Proband V2, male, 5 years old, has not completely lost the deciduous teeth, but the medullary root canal has a tendency to be locked, and the previous teeth were obvious. The deciduous teeth were excessively worn, but no periapical shadows were seen, and the development of permanent tooth germs was not abnormal. The clinical presentation of the patient is consistent with the main characteristics of hereditary opalescent dentin. Other patients in the family also have the main characteristics of the disease. The transmission of pathogenic genes is consistent with autosomal dominant genetic characteristics. We analyzed the DNA of 13 of these family members (of which 10 were patients).
1.2连锁分析  1.2 linkage analysis
1.2.1 外周血细胞 DNA的提取 在征得受试者的同意后, 从 13个家庭成 员中分别静脉采血 5 ml, 加抗凝剂, 立即混匀。 4°C , 3000rpm 离心 15 分 钟, 用吸管吸弃上层血浆。 在剩余溶液中加入 5至 10倍的双蒸水, 室温静置 10分钟。 4°C , 3500 rpm 离心 15分钟。 用真空泵吸弃上清, 加 15mmol / L TES (15 mmol/L Tris-HCl pH8.0, 15 mmol/L EDTA pH8.0, 15 mmol/L N aCl 4 ml), 重悬沉淀。 加入 270 μ 1 10 %的 SDS混匀, 再加入 40 μ 1的蛋白 酶 K ( 10 mg / ml ) , 混匀。 50°C2小时后, 37°C过夜。 冰浴冷却至 0°C, 加 1倍体积的酚, 混匀, 4°C , 3500 rpm离心 15分钟。 取上清, 用酚再抽提一 次。 取上清, 加 1倍体积的氯仿: 异戊醇(24 : 1 ) , 混匀, 室温 5分钟, 4 °C , 3500rpm离心 5分钟, 取上清。 用氯仿: 异戊醇 (24 : 1再抽提一次) 再抽提一次。 取上清, 加入 2.5倍冰预冷 95%乙醇, 轻摇直到 DNA析出、 成 团。 用 70%乙醇洗涤 1次。 最后把 DNA吸入 1.5ml的离心管中, 干燥, 回溶 于 1.0 ml TE中。 待溶解后, 用紫外分光光度计定量。 1.2.1 Extraction of DNA from peripheral blood cells After obtaining the consent of the subjects, 5 ml of blood was collected from 13 family members by intravenous injection, and anticoagulants were added and mixed immediately. Centrifuge at 4 ° C, 3000rpm for 15 minutes, and aspirate the upper plasma with a pipette. Add 5 to 10 times double distilled water to the remaining solution and let stand at room temperature for 10 minutes. Centrifuge at 4 ° C, 3500 rpm for 15 minutes. Discard the supernatant with a vacuum pump, add 15 mmol / L TES (15 mmol / L Tris-HCl pH8.0, 15 mmol / L EDTA pH8.0, 15 mmol / LN aCl 4 ml), and resuspend the pellet. Add 270 μ 1 of 10% SDS and mix, and then add 40 μ 1 of proteinase K (10 mg / ml) and mix. After 2 hours at 50 ° C, overnight at 37 ° C. Cool to 0 ° C in an ice bath, add 1 volume of phenol, mix and centrifuge at 4 ° C, 3500 rpm for 15 minutes. The supernatant was taken and extracted again with phenol. Take the supernatant, add 1 volume of chloroform: isoamyl alcohol (24: 1), mix, and centrifuge at room temperature for 5 minutes, 4 ° C, 3500 rpm for 5 minutes, and take the supernatant. Extract with chloroform: isoamyl alcohol (24: 1 again). Take the supernatant, add 2.5 times ice to pre-cool 95% ethanol, and shake gently until the DNA is precipitated and clumped. Wash once with 70% ethanol. Finally, the DNA was sucked into a 1.5ml centrifuge tube, dried and reconstituted. In 1.0 ml TE. After dissolution, quantify with UV spectrophotometer.
1.2.2 STRPs荧光标记 PCR及 PCR产物分析扫描  1.2.2 STRPs fluorescently labeled PCR and PCR product analysis scan
(1) STRPs引物的选择  (1) Selection of STRPs primers
选取 4q21上的 8个标记丈连锁分析。八个 STRPs标记分别为: D4S2915, D4S2932, GATA62A11, D4S2409, DSP STRP, SPP1, D4S1563, D4S1544。 八个 STRPs引物序列见表 1。 以上述 8对引物, 在 Perkin Elmer 9600型热 循环仪上进行 PCR, 反应体系为 12.5 μ 1 ( 10 x PCR緩冲液 1.25 μ 1, 2 mmol/L dNTPs 0.5 μ ld TP(Sigma公司产品), 1% FdNTP 0.5 μΐ, 2W μ\ Taq聚合酶(购自原平皓生物技术有限公司) 0.25 μ 1, 5 pmol/ μ 1 primer 0.25 μΐ, 40 ng/μΐ Genomic DNA 1.0 μ1)。 PCR反应条件为 94 °C 变性 50 s, 退火 1 min (退火温度见表 1), 72°C延伸 50 s, 35 个循环, 最后 72°C延伸 5 min。  Eight markers on 4q21 were selected for linkage analysis. The eight STRPs are marked as: D4S2915, D4S2932, GATA62A11, D4S2409, DSP STRP, SPP1, D4S1563, D4S1544. The primer sequences of eight STRPs are shown in Table 1. PCR was performed on a Perkin Elmer 9600 thermal cycler with the above 8 pairs of primers. The reaction system was 12.5 μ 1 (10 x PCR buffer 1.25 μ 1, 2 mmol / L dNTPs 0.5 μ ld TP (product of Sigma)). 1% FdNTP 0.5 μΐ, 2W μ \ Taq polymerase (purchased from the original Pinghao Biotechnology Co., Ltd.) 0.25 μ 1, 5 pmol / μ 1 primer 0.25 μΐ, 40 ng / μΐ Genomic DNA 1.0 μ1). The PCR reaction conditions were denaturation at 94 ° C for 50 s, annealing for 1 min (annealing temperature see Table 1), extension at 72 ° C for 50 s, 35 cycles, and extension at 72 ° C for 5 min.
(2) STRPs等位片段分析  (2) Allele fragment analysis of STRPs
在 PCR产物能被把聚丙烯酰胺凝胶分开的情况下, 把同一个体的不同 位点的 PCR产物混合,取 2 μΙΡΟ反应的混合产物与 0.4 μΙΑΒΙΚΟΧ-400 分子量标准、 2.1 μΐ甲酰胺和 0.4 μΐ染料混合, 95°( 变性2 11 1, ;水浴迅 速冷却,在 Perkin Elmer公司 ABI377测序仪上, 4%聚丙烯酰胺和 36%尿 素中电泳 2 h, 用 GENESCAN2.1软件进行数据收集, 泳道线校正, 内在分 子量标准校正和迁移片段大小测量。 In the case that the PCR product can be separated from the polyacrylamide gel, the PCR products of different sites of the same individual are mixed, and the mixed product of the 2 μΙΡΟ reaction is taken with a molecular weight standard of 0.4 μΙΑΒΙΚΟχ-400, 2.1 μΐformamide and 0.4 μΐ Dye mix, 95 ° (denaturation 2 11 1,); water bath quickly cooled, electrophoresis on 4% polyacrylamide and 36% urea for 2 h on Perkin Elmer ABI377 sequencer, data collection using GENESCAN 2.1 software, lane line Calibration, intrinsic molecular weight calibration and migration fragment size measurement.
8个 STRPs标记的引物序列及 PCR反应的退火温度 位点 引物序列 退火温度8 STRPs-labeled primer sequences and annealing temperature sites for PCR reactions Primer sequences Annealing temperature
D4S2915 5'引物 TTTTAGAAATAGTTGTCAACCTTCC 50 °C D4S2915 5 'Primer TTTTAGAAATAGTTGTCAACCTTCC 50 ° C
4^^ 463668. 3'引物 TATAAGACCTTTACACTGATAACCA  4 ^^ 463668. 3 'primer TATAAGACCTTTACACTGATAACCA
D4S2932 ^^ 39368 51'引物 GAGCAAAACTCTGTCTCAAAAATAA 55 °C  D4S2932 ^^ 39368 51 'primer GAGCAAAACTCTGTCTCAAAAATAA 55 ° C
3'引物 GGCTTACTTGGAAAGGTCTCTT  3 'Primer GGCTTACTTGGAAAGGTCTCTT
GATA62A11 5'引物 AACTTCACCATAGTGCCAGC 62 °C  GATA62A11 5 'primer AACTTCACCATAGTGCCAGC 62 ° C
3'引物 GACAAAATCCCTCTGTGCAT  3 'Primer GACAAAATCCCTCTGTGCAT
D4S2409 5'引物 ACTTTACCCCACAAGCATTG 50°C  D4S2409 5 'Primer ACTTTACCCCACAAGCATTG 50 ° C
3'引物 CCATCCACCCTCAATACTTG 3 'Primer CCATCCACCCTCAATACTTG
4 245751  4 245751
DSP STRP 5'引物 TCTG¾364563 8ATTAGATCATACTTTGGC 58 °C  DSP STRP 5 'Primer TCTG¾364563 8ATTAGATCATACTTTGGC 58 ° C
3'引物 ATACTGGCTATTGAAAAGGTTC  3 'Primer ATACTGGCTATTGAAAAGGTTC
SPP1 5'引物 TCAGGTGATGCTTCTGCCTC 63 °C  SPP1 5 'Primer TCAGGTGATGCTTCTGCCTC 63 ° C
3'引物 TGAGCCCAGGAGTTTAAGGC  3 'Primer TGAGCCCAGGAGTTTAAGGC
D4S1563 5'引物 GCTGCCTGACACACTGG 56°C  D4S1563 5 'Primer GCTGCCTGACACACTGG 56 ° C
3'引物 ACTATTGCTGTTGCTGACCC  3 'primer ACTATTGCTGTTGCTGACCC
D4S1544 5'引物 CCATATAACACAATGGATATAGC 55 °C  D4S1544 5 'Primer CCATATAACACAATGGATATAGC 55 ° C
3'引物 CAGAAACTCCAGCAGAGACT  3 'Primer CAGAAACTCCAGCAGAGACT
1.2.3 连锁分析 用 LINKAGE软件包的 MLINK连锁分析软件, 在常 染色体显性遗传两等位基因系统的模式下, 设定在杂合子中致病基因频率 o o 1.2.3 Linkage analysis Using the MLINK linkage analysis software of the LINKAGE software package, under the mode of autosomal dominant inheritance two allele system, set the frequency of disease-causing genes in heterozygotes o o
和外显率分别为 0.00001和 0.99, 设定等位片段具有相同的频率, 3581分别在重 组率为 0, 0.01 , 0.05, 0.1, 0.2, 0.3, 0.4 时计算 Lod值, 结果见表 2。 以 Lod 值>1判断, 遗传性乳光牙本质的致病基因定位在染色体 4q。  And the penetrance are 0.00001 and 0.99 respectively, and the alleles are set to have the same frequency. The 3581 calculates the Lod values when the recombination rates are 0, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4. Judging by the Lod value> 1, the pathogenic gene of hereditary opalescent dentin was located on chromosome 4q.
表 2. 8个 STRPs与遗传性乳光牙本质的 2 点 Lod值连锁分析结果 Table 2.Results of two-point Lod linkage analysis between 8 STRPs and hereditary opalescent dentin
Lod Score at a Recombination fraction of: Lod Score at a Recombination fraction of:
Locus 0.00 0.01 0.05 0.10 0.20 0.30 0.40 Zmax ΘLocus 0.00 0.01 0.05 0.10 0.20 0.30 0.40 Zmax Θ
D4S2915 1.40 1.13 0.82 0.50 0.21 0.00D4S2915 1.40 1.13 0.82 0.50 0.21 0.00
D4S2932 1.66 1.35 0.99 0.61 0.23 0.00D4S2932 1.66 1.35 0.99 0.61 0.23 0.00
GATA62A11 1.60 1.27 0.90 0.51 0.16 0.00GATA62A11 1.60 1.27 0.90 0.51 0.16 0.00
D4S2409 1.32 0.97 0.64 0.35 0.11 0.00D4S2409 1.32 0.97 0.64 0.35 0.11 0.00
DSP STRP 1.63 1.28 0.80 0.38 0.08
Figure imgf000007_0001
0.00
DSP STRP 1.63 1.28 0.80 0.38 0.08
Figure imgf000007_0001
0.00
SPP1 0 0.79 0 0.65 0.49 0.33 0.17 0.00SPP1 0 0.79 0 0.65 0.49 0.33 0.17 0.00
D4S1563 0.00 0 0.65 0.54 0.32 0.12 0.12D4S1563 0.00 0 0.65 0.54 0.32 0.12 0.12
D4S1544 -0.92 -0.08 0.05 0.08 0.06 0.31 实施例 2 D4S1544 -0.92 -0.08 0.05 0.08 0.06 0.31 Example 2
侯选基因的突变筛查  Screening for mutations in candidate genes
选取 dspp作为侯选基因进行突变筛查。 用软件 Primer 3针对前 4个外 显子设计 PCR引物以进行巢式 PCR反应,共 8对引物(表 2 )。 Elout、 E2out、 E34fout和 E341out为第一轮 PCR反应的引物, Elin、 E2in、 E34fin和 E341in 为第二轮 PCR反应的引物。第一轮 PCR反应的前 3对引物的反应体系为 50 μ ΐ:  Select dspp as candidate gene for mutation screening. Primer 3 software was used to design PCR primers for the first 4 exons for nested PCR reaction, a total of 8 pairs of primers (Table 2). Elout, E2out, E34fout, and E341out are the primers for the first round of PCR reactions, and Elin, E2in, E34fin, and E341in are the primers for the second round of PCR reactions. The reaction system for the first 3 primers of the first PCR reaction is 50 μΐ:
10 X PCR緩冲液 5 μ ΐ  10 X PCR buffer 5 μΐ
2 mmol/L dNTPs 5 μ ΐ  2 mmol / L dNTPs 5 μ ΐ
5 pmol/ μ 1 primer 5 μ 1  5 pmol / μ 1 primer 5 μ 1
2U/ l Taq聚合酶 1 μ ΐ  2U / l Taq polymerase 1 μ ΐ
50 ng/ μ 1 Genomic DNA 1 μ 1  50 ng / μ 1 Genomic DNA 1 μ 1
加水至 50 μ 1。 反应条件为 94 °C 30秒, 退火 30秒, 72°C延伸 (退火 温度及延伸时间见表 3 ), 30个循环。 最后 72°C延伸 5 min。 表 3 引物序列及 PCR反应的退火和延伸温度 引物名称 引物序列 退火温度 延伸时间 Add water to 50 μ1. The reaction conditions were 94 ° C for 30 seconds, annealing for 30 seconds, and 72 ° C extension (see Table 3 for annealing temperature and extension time) for 30 cycles. Finally, extend at 72 ° C for 5 min. Table 3 Primer sequences and annealing and extension temperatures for PCR reactions Primer names Primer sequences Annealing temperature Extension time
Elout 5'引物 ATTGTCATGCAAAAGTCCAG 59 °C 60秒 Elout 5 'Primer ATTGTCATGCAAAAGTCCAG 59 ° C 60 seconds
3'引物 CAATAAAAATGGCCCAGGTG  3 'Primer CAATAAAAATGGCCCAGGTG
E2out 5'引物 TGTTTTCCTTCATTGGCACA 55。C 100秒  E2out 5 'primer TGTTTTCCTTCATTGGCACA 55. C 100 seconds
3'引物 AAACATGATGGCTGGCTAGT  3 'Primer AAACATGATGGCTGGCTAGT
E34fout 5'引物 GGGCTGATCTAACACGTCCA 55 °C 100秒  E34fout 5 'Primer GGGCTGATCTAACACGTCCA 55 ° C 100 seconds
3'引物 CCTCGTTTCTACAGGAATTCTCA  3 'Primer CCTCGTTTCTACAGGAATTCTCA
E341out 5'引物 GCATCCAGGGACAAGTAAGC 见正文 见正文  E341out 5 'primer GCATCCAGGGACAAGTAAGC See text See text
3'引物 TGTAATTGAAAGCATCCTGGTG  3 'Primer TGTAATTGAAAGCATCCTGGTG
Elin 5'引物 ATTGTCATGCAAAAGTCCAG 61 °C 60秒  Elin 5 'Primer ATTGTCATGCAAAAGTCCAG 61 ° C 60 seconds
3'引物 CTTGTTTGAAAGCCCAAGGT  3 'primer CTTGTTTGAAAGCCCAAGGT
E2in 5'引物 GATGTCCCCATAACCACACC 63 °C 100秒  E2in 5 'Primer GATGTCCCCATAACCACACC 63 ° C 100 seconds
3'引物 TCCAAATTTTCCACAGTGAGC  3 'Primer TCCAAATTTTCCACAGTGAGC
E34fin 5'引物 CAAGCCCTGTAAGAAGCCACT 63 °C 100秒  E34fin 5 'Primer CAAGCCCTGTAAGAAGCCACT 63 ° C 100 seconds
3'引物 TGCTTCCAGCTACTTGAGGTC  3 'Primer TGCTTCCAGCTACTTGAGGTC
E341in 5'引物 AGCCACAAACAGAAGCAACA 见正文 见正文  E341in 5 'Primer AGCCACAAACAGAAGCAACA See text See text
3'引物 TCATCCACATTCCTACCCAGT E341out的反应体系为 50 μ 1: 3 'Primer TCATCCACATTCCTACCCAGT The reaction system of E341out is 50 μ 1:
其中 Mixl 2 mmol/L dNTPs 8.75 μ 1  Of which Mixl 2 mmol / L dNTPs 8.75 μ 1
5 pmol/ μ 1 primer 2.4 μ 1  5 pmol / μ 1 primer 2.4 μ 1
50 ng/ μ 1 Genomic DNA 1 μ 1  50 ng / μ 1 Genomic DNA 1 μ 1
加水至 25 μ 1。  Add water to 25 μ1.
Mix2 10 x PCR緩冲液 5 μ ΐ  Mix2 10 x PCR buffer 5 μΐ
Expand Long Template ( Roche产品) 0.75 μ 1  Expand Long Template (Roche product) 0.75 μ 1
加水至 25 μ 1。  Add water to 25 μ1.
再把 Mixl和 Mix2混合。 反应条件为:  Mix Mixl and Mix2. The reaction conditions are:
94 °C 10秒, 55 °C 30秒, 68 °C 2分钟, 10个循环,  94 ° C for 10 seconds, 55 ° C for 30 seconds, 68 ° C for 2 minutes, 10 cycles,
94 °C 10秒, 63 °C 30秒, 68°C 2分钟 +20秒 I每个循环, 20个循环, 最后接 68 °C 7分钟。 取 5 μ ΐ PCR产物进行电泳分离, 电压 90V, 电 泳时间 15分钟, 电泳完、 拍照存档。 取第一轮 PCR产物稀释 250-1250倍, 进行第二轮 PCR反应。 反应条件为: 94°C 10秒, 退火 30秒, 72°C延伸, 25个循环, (退火温度及延伸时间见表 2 )。 取 PCR产物电泳、 拍照存档。 取第二轮 PCR产物, 以 PCR引物为测序引物直接测序。 将所得到的序列图 谱进行分析, 凡有杂和双峰处, 说明该位点为杂和状态, 需进一步分析。 对包含杂和状态位点的序列与 Genebank的序列进行比较并按正常读码框架 进行翻译。 发现患者的笫三外显子有一个无义突变, 其中的 DSPP 的第三 个外显子的第 3658位核苷酸由 C突变为 T, 从而导致 dspp的第 45位由正 常的编码谷氨酰胺的密码子 CAG变为终止密码子 TAG, 结果使 dspp翻译 提前终止, dspp基因的表达产物之一 DPP便不能产生 (图 2)。 实施例 3 酶切鉴定: 94 ° C for 10 seconds, 63 ° C for 30 seconds, 68 ° C for 2 minutes + 20 seconds per cycle, 20 cycles, and finally 68 ° C for 7 minutes. Take 5 μΐ of PCR products for electrophoresis separation, voltage 90V, electrophoresis time 15 minutes, electrophoresis is completed, and pictures are archived. Take the first round of PCR product diluted 250-1250 times and perform the second round of PCR reaction. The reaction conditions are: 94 ° C for 10 seconds, annealing for 30 seconds, 72 ° C extension, 25 cycles, (see Table 2 for annealing temperature and extension time). Take PCR products for electrophoresis and take pictures for archiving. The second round of PCR products was taken and directly sequenced using PCR primers as sequencing primers. The obtained sequence map is analyzed. Where there are impurities and double peaks, it indicates that the site is heterogeneous and needs further analysis. The sequences containing hetero and status sites were compared with those of Genebank and translated according to the normal reading frame. It was found that the patient had a nonsense mutation in exon III, in which the 3658th nucleotide of DSPP 3 exon was mutated from C to T, which caused the 45th position of dspp to be normally encoded by glutamine. The codon CAG of the amide was changed to the stop codon TAG, and as a result, the translation of dspp was terminated early, and DPP, one of the expression products of the dspp gene, could not be produced (Figure 2). Example 3 Identification by enzyme digestion:
3.1 PCR反应 用 E34fout引物先做第一轮 PCR反应, 反应完毕后, 电泳、 拍照存档。 然后取笫一轮 PCR产物稀释 250倍, 用 E341out进行第 二轮 PCR反应,反应体系 100μ1,反应条件同突变筛查部分。取第二轮 PCR 产物电泳、 拍照存档。  3.1 PCR reaction The first round of PCR reaction was performed with E34fout primers. After the reaction was completed, electrophoresis and photos were archived. Then take one round of the PCR product and dilute it 250 times, and use E341out for the second round of PCR reaction. The reaction system is 100μ1. The reaction conditions are the same as those of the mutation screening section. Take the second round of PCR products for electrophoresis and take pictures for archiving.
3.2 PCR反应回收(PCR回收试剂盒为 Life Technologies的 Concert Papid PCR Purfication System )  3.2 PCR reaction recovery (PCR recovery kit is Life Technologies Concert Papid PCR Purfication System)
取 4 ml洗涤緩冲液, 加 10 ml 95%乙醇, 混匀。  Take 4 ml of washing buffer, add 10 ml of 95% ethanol, and mix well.
加 400 μ 1结合緩冲液到 90 μ 1 PCR产物中, 混匀。  Add 400 μl of binding buffer to 90 μl of PCR product and mix well.
把混合液加到柱(cartridge) 中央, 28°C, ll,900g, 离心 1分钟, 弃 去流出的液体。  Add the mixed solution to the center of the cartridge, 28 ° C, ll, 900g, centrifuge for 1 minute, and discard the flow-out liquid.
加 700 μΐ的洗涂緩冲液(含乙醇), 20 °C, ll,900g, 离心 1分钟, 弃去流出的液体, 20 °C, ll,900g, 离心 1分钟。  Add 700 μΐ of wash buffer (containing ethanol), 20 ° C, ll, 900g, and centrifuge for 1 minute. Discard the flow-out liquid, 20 ° C, ll, 900g, and centrifuge for 1 minute.
把柱子换到 1.5 ml的回收离心管中, 加预热到 65°C的 50 μΐ ΤΕ緩 冲液 (pH8.0,10 mmol/L Tris.Cl, lmmol/L EDTA), R.T. 1分钟, ll,900g, 离 心 2分钟。 取 5 μΐ回收产物琼脂糖(BIOWEST公司产品) 电泳,,拍照, 存档。  Transfer the column to a 1.5 ml recovery centrifuge tube, and add 50 μΐ TE buffer (pH 8.0, 10 mmol / L Tris.Cl, 1 mmol / L EDTA) pre-heated to 65 ° C, RT for 1 minute, ll , 900g, centrifuge for 2 minutes. Take 5 μΐ of the recovered agarose (product of BIOWEST company), electrophoresis, take pictures, and archive.
3.3. Rsal酶切  3.3. Rsal digestion
酶切体系 15 μΐ:  Digestion system 15 μΐ:
BSA ( lOmg/ml) 0.15 μΐ  BSA (lOmg / ml) 0.15 μΐ
10倍緩冲液 1.5 μΐ  10x buffer 1.5 μΐ
Rsal ( Promega产口 ) (10 U/ μ 1) 1 μΐ  Rsal (promega) (10 U / μ 1) 1 μΐ
PCR产物 12.35 μΐ  PCR product 12.35 μΐ
37°C, 2小时。 酶切反应完毕后, 取 15 μΐ反应混合物琼脂糖电泳, 照相。 发现此家系的正常个体的 PCR产物可被限制性内切酶 Rsal完全酶解, 而受 累个体因为无义突变破坏了 Rsal识别位点, 导致在琼脂糖电泳后出现一条 较大条带 (图 3)。 51个无关正常个体 PCR产物也可被 Rsal完全酶解 c 实施例 4 37 ° C, 2 hours. After the digestion reaction was completed, 15 μΐ of the reaction mixture was subjected to agarose electrophoresis and photographed. It was found that the PCR products of normal individuals of this family can be completely digested by the restriction enzyme Rsal, and the affected individuals damaged the Rsal recognition site because of a nonsense mutation, resulting in a band after agarose electrophoresis. Larger bands (Figure 3). 51 unrelated normal individuals may also be Rsal PCR product was digested completely c Example 4
遗传性乳光牙本质疾病诊断的试剂盒及应用  Kit for diagnosis of hereditary opalescent dentin disease and application thereof
试剂盒含有:  The kit contains:
外侧 5' 引物 (5 pmol/ μ 1)  Outer 5 'primer (5 pmol / μ 1)
外侧 3' 引物 (5 pmol/ μ 1)  Outer 3 'primer (5 pmol / μ 1)
内側 5' 引物 (5 pmol/ μ 1)  Inner 5 'primer (5 pmol / μ 1)
内側 3' 引物 (5 pmol/ μ 1)  Inner 3 'primer (5 pmol / μ 1)
10倍 PCR反应緩冲液  10x PCR reaction buffer
dNTP ( 2mmol/ μ 1)  dNTP (2mmol / μ 1)
Taq DNA聚合酶  Taq DNA polymerase
MgCl2 MgCl 2
限制性内切酶 Rasl  Restriction enzyme Rasl
限制性内切酶 10倍反应緩冲液  Restriction enzyme 10-fold reaction buffer
BSA ( lOmg/ml ) 使用时用外侧 5'引物和外侧 3'引物先做第一轮 PCR反应, 反应完毕后, 电泳、 拍照存档。 然后取第一轮 PCR产物稀释 250倍做模板, 用内侧 5'引 物和内侧 3'引物进行第二轮 PCR反应,, 取第二轮 PCR产物电泳、 拍照存 档。 用 MgCl2调整 PCR产物的离子强度,加入限制性内切酶 Rsal, 37 °C 2 h (BSA 10 mg/ml 0.15 μ 1,10倍緩冲液 1.5 μ 1, (Rsal lO U/ μ Ι) 1 μ 1, PCR产 物 12.35 μ 1)。 酶切反应完毕后, 取 15 μ 1反应混合物琼脂糖电泳, 照相。 正常个体的 PCR产物可被限制性内切酶 Rsal完全酶解, 而受累个体因为无 义突变破坏了 Rsal识别位点, 导致在琼脂糖电泳后出现一条较大条带。 这 样通过待测个体的 dspp基因的部分测序图谱就可其是否为遗传性乳光牙本 质病患者。 When using BSA (10mg / ml), use the outer 5 'primer and the outer 3' primer to do the first round of PCR reaction. After the reaction is completed, electrophoresis and photographing are archived. Then take the first round of PCR product diluted 250 times as a template, use the inner 5 'primer and the inner 3' primer for the second round of PCR reaction, take the second round of PCR product electrophoresis, and take pictures for archiving. Adjust the ionic strength of the PCR product with MgCl 2 and add the restriction enzyme Rsal, 37 ° C for 2 h (BSA 10 mg / ml 0.15 μ 1, 10-fold buffer 1.5 μ 1, (Rsal 10 U / μ Ι) 1 μ1, PCR product 12.35 μ 1). After the digestion reaction was completed, 15 μl of the reaction mixture was subjected to agarose electrophoresis and photographed. The PCR products of normal individuals can be completely digested by the restriction enzyme Rsal, and the affected individuals' Rsal recognition sites are destroyed by nonsense mutations, resulting in a larger band after agarose electrophoresis. In this way, it can be determined whether the dspp gene of the individual to be tested is hereditary opalescent tooth Patients with dysfunction.
应理解, 在阅读了本发明的上述讲授内容之后, 本领域技术人员可以 对本发明作各种改动或修改, 但改动或修改的等价形式同样落在本申请权 利要求书所限定的范围内。  It should be understood that after reading the above-mentioned teaching content of the present invention, those skilled in the art can make various changes or modifications to the present invention, but the equivalent forms of the changes or modifications also fall within the scope defined by the claims of this application.

Claims

权利要求书 Claim
1、 检测遗传性乳光牙本质的突变基因 dspp的方法, 其特征在于该方法 包括直接测序法、 限制性内切酶法或寡核苷酸探针杂交法。 1. A method for detecting a mutant gene dspp of hereditary opalescent dentin, characterized in that the method includes a direct sequencing method, a restriction enzyme method or an oligonucleotide probe hybridization method.
2、 如权利要求 1所述突变基因 dspp的检测方法, 其中的突变基因的突 变位点位于 DSPP的第三个外显子处。  2. The method for detecting a mutant gene dspp according to claim 1, wherein the mutation site of the mutant gene is located at the third exon of the DSPP.
3、 如权利要求 2所述突变基因 dspp的检测方法, 其中的 dspp的第三 个外显子的第 3658位核苷酸由 C突变为 T, 从而导致 dspp的第 45位由正 常的编码谷氨酰胺的密码子 CAG变为终止密码子 TAG。  3. The method for detecting a mutant gene dspp according to claim 2, wherein the 3658th nucleotide of the third exon of dspp is mutated from C to T, so that the 45th position of dspp is normally encoded The amino acid codon CAG becomes the stop codon TAG.
4、权利要求 2或 3所迷突变基因的检测方法,其特征在于包括如下步骤: A: 选取 dspp作为侯选基因进行突变筛查, 针对 dspp基因的前 4 个外显子设计 PCR引物, 以进行 PCR反应;  4. The method for detecting a mutant gene according to claim 2 or 3, comprising the steps of: A: selecting dspp as a candidate gene for mutation screening, designing PCR primers for the first four exons of the dspp gene, and Perform a PCR reaction;
B: PCR反应产物经纯化后直接测序或克隆后测序。 将所得到的序 列与 Genebank 中的序列比较并按正常读码框架进行翻译以确定 dspp基因 的突变位点。  B: The PCR reaction product is purified and directly sequenced or cloned and sequenced. The resulting sequence was compared with the sequence in Genebank and translated according to the normal reading frame to determine the mutation site of the dspp gene.
5、权利要求 2或 3所迷突变基因的检测方法,其特征在于包括如下步骤: A: 提取 DNA, 在突变位点附近设计 PCR引物, 进行 PCR反应; B: PCR反应产物经纯化,或用 ]^^(¾直接调节 PCR反应产物的 MgCl2 浓度后, 用限制性内切酶 Rsal酶切, 酶切反应完毕后, 取反应混合物琼脂 糖电泳, 照相, 以确定突变基因。 5. The method for detecting a mutant gene according to claim 2 or 3, comprising the steps of: A: extracting DNA, designing PCR primers near the mutation site, and performing a PCR reaction; B: purifying the PCR reaction product, or using ] ^^ (¾ After directly adjusting the MgCl 2 concentration of the PCR reaction product, use the restriction endonuclease Rsal to cut it. After the digestion reaction is complete, take the reaction mixture agarose electrophoresis and take pictures to determine the mutant gene.
6、 依据权利要求 5的方法制备而成的试剂盒, 其包括:  6. A kit prepared according to the method of claim 5, comprising:
外侧 5' 引物  5 'outside primer
外侧 3' 引物  Outer 3 'primer
内侧 5' 引物  Medial 5 'primer
内倒 3' 引物  Inverted 3 'primer
10倍 PCR反应緩冲液 dNTP 10x PCR reaction buffer dNTP
Taq DNA聚合酶  Taq DNA polymerase
MgCl2 MgCl 2
限制性内切酶 Rsal  Restriction enzyme Rsal
限制性内切酶 10倍反应緩冲液  Restriction enzyme 10-fold reaction buffer
BSA  BSA
7、 权利要求 1 ~ 6其中之一的 DSPP突变基因在遗传性乳光牙本质治疗 中的应用。  7. The use of the DSPP mutant gene of one of claims 1 to 6 in the treatment of hereditary opalescent dentin.
8、 权利要求 6所述试剂盒在遗传性乳光牙本质的检测方法中的应用。  8. Use of the kit according to claim 6 in a method for detecting hereditary opalescent dentin.
9、 权利要求 6所述试剂盒在遗传性乳光牙本质的治疗方法中的应用。 9. Use of the kit according to claim 6 in a method for treating hereditary opalescent dentin.
PCT/CN2000/000280 2000-09-15 2000-09-15 The method of detecting mutant dspp gene of hereditary opalescent WO2002022864A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2002527304A JP3886901B2 (en) 2000-09-15 2000-09-15 Method for detecting mutant gene dspp in hereditary milky white elephant
CNB00819646XA CN1257986C (en) 2000-09-15 2000-09-15 The method of detecting mutant DSPP gene of hereditary opalescent dentin
DE10085485T DE10085485B4 (en) 2000-09-15 2000-09-15 Method for detecting the mutant gene dspp of hereditary opalescent dentin
AU2000272670A AU2000272670A1 (en) 2000-09-15 2000-09-15 The method of detecting mutant dspp gene of hereditary opalescent
PCT/CN2000/000280 WO2002022864A1 (en) 2000-09-15 2000-09-15 The method of detecting mutant dspp gene of hereditary opalescent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2000/000280 WO2002022864A1 (en) 2000-09-15 2000-09-15 The method of detecting mutant dspp gene of hereditary opalescent

Publications (1)

Publication Number Publication Date
WO2002022864A1 true WO2002022864A1 (en) 2002-03-21

Family

ID=4574698

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2000/000280 WO2002022864A1 (en) 2000-09-15 2000-09-15 The method of detecting mutant dspp gene of hereditary opalescent

Country Status (5)

Country Link
JP (1) JP3886901B2 (en)
CN (1) CN1257986C (en)
AU (1) AU2000272670A1 (en)
DE (1) DE10085485B4 (en)
WO (1) WO2002022864A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1323427A4 (en) * 2000-09-05 2004-04-07 Shanghai Res Ct Of Biotechnolo Method for diagnosing and treating dentinogenesis imperfecta type ii by using dentin sialophosphoprotein (dspp) gene and its encoding product
CN114107398A (en) * 2020-08-27 2022-03-01 中国科学院分子细胞科学卓越创新中心 Construction method and application of point mutation animal model of dentinogenesis imperfecta

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103233076B (en) * 2013-05-13 2015-03-25 赤峰市农牧科学研究院 Detection method of real-time fluorescence quantification (PCR) for DSPP (dentin sialophosphoprotein) genes in incisors of guinea pig
WO2020235992A1 (en) * 2019-05-21 2020-11-26 Mimos Berhad System and method to detect and quantify a dssp molecule in a sample

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CYTOGENET. CELL GENET., vol. 79, no. 1-2, 1997, pages 121 - 122 *
EUR. J. ORAL SCI., vol. 106, no. SUPPL. 1, January 1998 (1998-01-01), pages 227 - 233 *
J. CRANIOFAC. GENET. DEV. BIOL., vol. 17, no. 4, October 1997 (1997-10-01) - December 1997 (1997-12-01), pages 172 - 177 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1323427A4 (en) * 2000-09-05 2004-04-07 Shanghai Res Ct Of Biotechnolo Method for diagnosing and treating dentinogenesis imperfecta type ii by using dentin sialophosphoprotein (dspp) gene and its encoding product
CN114107398A (en) * 2020-08-27 2022-03-01 中国科学院分子细胞科学卓越创新中心 Construction method and application of point mutation animal model of dentinogenesis imperfecta
CN114107398B (en) * 2020-08-27 2023-11-03 中国科学院分子细胞科学卓越创新中心 Construction method and application of point mutation animal model of dentin hypoplasia

Also Published As

Publication number Publication date
JP2004508067A (en) 2004-03-18
JP3886901B2 (en) 2007-02-28
CN1454264A (en) 2003-11-05
DE10085485T1 (en) 2003-10-16
AU2000272670A1 (en) 2002-03-26
CN1257986C (en) 2006-05-31
DE10085485B4 (en) 2005-12-08

Similar Documents

Publication Publication Date Title
Bader et al. X-linked retinitis pigmentosa: RPGR mutations in most families with definite X linkage and clustering of mutations in a short sequence stretch of exon ORF15
JP2004159661A (en) Detection of neoplasm by saliva analysis
AU2016351311B2 (en) SCAP gene mutant and the application thereof
WO2002022864A1 (en) The method of detecting mutant dspp gene of hereditary opalescent
CN114875148A (en) Familial multiple lipoma detection kit and application of primer group
CN111139297B (en) Kit for preimplantation embryo genetic diagnosis and prenatal diagnosis of DMD
CN111073977A (en) Mutation detection kit for pathogenic gene SLC26A4 of vestibular aqueduct enlargement/Pendred syndrome
CN111321215A (en) Congenital aniridia pathogenic gene mutation detection kit and application thereof
CN108866067B (en) Pathogenic mutation of Leber congenital amaurosis and detection reagent thereof
CN111154883A (en) Breast cancer related gene PIK3CA site g.179220986A & gtT mutant and application thereof
CN115927354B (en) SH3TC2 gene pathogenic mutant and application thereof in preparation of fibula muscular atrophy 4C type diagnostic kit
CN116004799B (en) CRTAP pathogenic mutant and application thereof in preparation of gristle syndrome VII type diagnosis kit
EP1352092B1 (en) Mutations in the ferroportin 1 gene associated with hereditary haemochromatosis
EP1130122A2 (en) Methods for the diagnosis of polymorphisms in the human EP1-R gene
CN114622013B (en) Juvenile idiopathic scoliosis detection product
CN111139301B (en) Breast cancer related gene ERBB2 site g.39397319C > A mutant and application thereof
JP2000316577A (en) Diagnosis of citrullinemia type ii onset in adult
CN115873861B (en) PAH pathogenic mutant and application thereof in preparation of phenylketonuria diagnostic kit
CN112941186B (en) Breast cancer susceptibility gene BRCA2-K2305N mutant and specific primer thereof
US7897739B2 (en) Method for diagnosing diabetic retinopathy by single nucleotide polymorphism, DNA fragment thereof, and primer thereof
JP3682688B2 (en) Osteoporosis drug sensitivity prediction method and reagent kit therefor
JP4219027B2 (en) Determination method and diagnosis kit for systemic lupus erythematosus
CN116024333A (en) Retinal pigment degeneration screening kit
CN117887828A (en) High myopia screening kit
CN115850430A (en) SCN1A mutant protein, SCN1A gene mutant, amplification primer, detection reagent and application

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 00819646X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2002527304

Country of ref document: JP

RET De translation (de og part 6b)

Ref document number: 10085485

Country of ref document: DE

Date of ref document: 20031016

Kind code of ref document: P

WWE Wipo information: entry into national phase

Ref document number: 10085485

Country of ref document: DE

122 Ep: pct application non-entry in european phase
REG Reference to national code

Ref country code: DE

Ref legal event code: 8607

REG Reference to national code

Ref country code: DE

Ref legal event code: 8607